Kasuya S, Izumi S
Department of Internal Medicine, Tohno Hospital, Kani City, Japan.
Pharmatherapeutica. 1988;5(3):177-82.
An open pilot study was carried out over a period of more than 2 years to assess the steroid-sparing effect of ketotifen (1 mg twice daily) in 12 steroid-dependent asthmatic patients. Daily steroid consumption (prednisolone equivalent) was calculated for the year before and for 1 and 2 years of ketotifen treatment from the total of all doses given throughout the year. Results showed that in 6 of the 12 patients who responded with reduced steroid consumption the mean daily dose decreased from 5.7 mg to 4.1 mg/day (p less than 0.05) in the first year of ketotifen: the final mean reduction rate at the end of the 2-year trail was 83.6% (p less than 0.005). Furthermore, the mean daily consumption of beta 2-stimulants (salbutamol equivalent) decreased from 8.7 to 6.2 mg/day (p less than 0.025) in the responders. In the 6 non-responders, there was a slight increase in mean daily steroid consumption from 2.4 mg to 3.0 mg/day. The most frequently reported side-effect of ketotifen was dizziness, which occurred in one-third of the patients; all patients, however, were able to continue with treatment.
一项开放的前瞻性研究持续了两年多，以评估酮替芬（每日两次，每次1毫克）对12名依赖类固醇的哮喘患者的类固醇节省效果。根据全年给予的所有剂量计算出酮替芬治疗前一年以及治疗1年和2年的每日类固醇消耗量（相当于泼尼松龙）。结果显示，在12名对减少类固醇消耗有反应的患者中，有6名患者在酮替芬治疗的第一年，平均每日剂量从5.7毫克降至4.1毫克/天（p<0.05）：在为期2年的试验结束时，最终平均降低率为83.6%（p<0.005）。此外，有反应的患者中，β2激动剂（相当于沙丁胺醇）的平均每日消耗量从8.7毫克降至6.2毫克/天（p<0.025）。在6名无反应的患者中，平均每日类固醇消耗量从2.4毫克略有增加至3.0毫克/天。酮替芬最常报告的副作用是头晕，三分之一的患者出现了这种情况；然而，所有患者都能够继续治疗。
